Skip to main
IBIO

iBio (IBIO) Stock Forecast & Price Target

iBio (IBIO) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

iBio is a preclinical biotechnology company that leverages AI technology to develop precision antibodies. The company's first drug candidate aims to inhibit negative regulators of muscle growth, potentially preserving lean mass and improving body composition in obese patients. With upcoming milestones, strong partnerships, and a promising drug candidate, the market potential is significant, but investors should be aware of the highly competitive nature of the industry and the company's need for additional funding in the future.

Bears say

iBio is facing significant risks and uncertainties as a preclinical stage biotech company with a focus on AI-driven development of precision antibodies for obesity and cardiometabolic diseases. While its technology has potential, the need for additional funding and the potential impact of clinical trials on its stock make it a risky investment. The company's current valuation is based on projected future revenue and is subject to potential competition and regulatory challenges. The recent strong financial results and upcoming events may provide short-term positivity, but the long-term outlook remains uncertain and dependent on successful development and commercialization of its products.

iBio (IBIO) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of iBio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About iBio (IBIO) Forecast

Analysts have given iBio (IBIO) a Buy based on their latest research and market trends.

According to 4 analysts, iBio (IBIO) has a Buy consensus rating as of Apr 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

iBio (IBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.